STTK
Shattuck Labs, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.37
−0.92%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$5.51
From 52W high−33.37%
Volume869584.00
Market cap$538.95M
P/E (TTM)—
P/S (TTM)539.0x
Div yield—
Key dataOct 19, 2026
Open
$5.51
From 52W high
−33.37%
Volume
869584.00
Market cap
$538.95M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.8x
P/E (TTM)
—
RSI (14)
38.6
MomentumView details →
1D Return
−0.92%
YTD Return
+50.10%
SummaryUpdated Jun 1, 2026
Shattuck Labs, Inc. (NASDAQ:STTK) is a clinical-stage biotechnology company founded in 2016 and headquartered in Austin, Texas. The company went public in October 2020 and focuses on developing innovative therapeutics for cancer and autoimmune diseases. Shattuck Labs specializes in creating fusion proteins that can simultaneously target multiple pathways in the immune system, representing a novel approach to cancer immunotherapy. The company is currently advancing its lead drug candidate through Phase 1 clinical trials while developing additional programs through its proprietary platform technology.
Similar companies
Latest newsMore news →
Shattuck Labs, Inc. announced that it will present two posters at UEG Week 2026 in Barcelona.6d agoShattuck Labs appointed Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development, to lead the hidradenitis suppurativa clinical development program.18d agoShattuck Labs announced plans to evaluate SL-325 in a Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa, expected to initiate in 2026.18d ago